A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 Study

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00809510

Enrollment

Registered

2008-12-17

Start date

2009-01-31

Completion date

Unknown

Last updated

2011-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease

Brief summary

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

Interventions

DRUGABT-089

20 mg ABT-089 taken once-daily for 6 months

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

55 Years to 90 Years

Healthy volunteers

Inclusion criteria

* The subject was randomized into Study M06-876 and completed the study. * The subject must remain on the same dose of AChEI that was used during the M06-876 study. * The subject is in general good health, as judged by the investigator

Exclusion criteria

* The subject is currently, or plans to participate in another experimental study during the course of this trial. * The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.

Design outcomes

Primary

Measure	Time frame
Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)	Month 1, 2, 4, 6

Secondary

Measure	Time frame
ADAS-Cog, CIBIC-plus, MMSE, QoL-AD	Month 1, 2, 4, 6

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026